News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,801 Results
Type
Article (14259)
Company Profile (105)
Press Release (259429)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88268)
Career Advice (465)
Deals (15391)
Drug Delivery (73)
Drug Development (36714)
Employer Resources (50)
FDA (6382)
Job Trends (6232)
News (150696)
Policy (14129)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23317)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (99)
Approvals (6573)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1317)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (150)
Cervical cancer (9)
Clinical research (32018)
Collaboration (725)
Compensation (325)
Complete response letters (33)
COVID-19 (778)
CRISPR (43)
C-suite (432)
Cystic fibrosis (58)
Data (1821)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1382)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33459)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (38977)
Executive appointments (528)
FDA (7480)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (428)
Gene editing (70)
Generative AI (18)
Gene therapy (165)
GLP-1 (439)
Government (1404)
Grass and pollen (4)
Guidances (164)
Healthcare (3575)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (842)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5913)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3448)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1302)
Medtech (1309)
Mergers & acquisitions (9898)
Metabolic disorders (434)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (37)
Neuroscience (887)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (600)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29741)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8305)
Phase 2 (13518)
Phase 3 (12211)
Pipeline (1904)
Policy (135)
Postmarket research (1401)
Preclinical (3338)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2659)
Recruiting (18)
Regulatory (10955)
Reports (15)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1644)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Today (5)
Last 7 days (177)
Last 30 days (748)
Last 365 days (10437)
2026 (951)
2025 (10712)
2024 (12498)
2023 (14246)
2022 (19557)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20889)
Australia (2687)
California (3177)
Canada (1481)
China (550)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (40869)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2586)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1396)
New Mexico (7)
New York (906)
North Carolina (619)
North Dakota (2)
Northern California (1447)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1387)
Tennessee (53)
Texas (454)
United States (12668)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
273,801 Results for "tremeau pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th
Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th.
October 20, 2022
·
3 min read
Genetown
Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX
Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatology’s (ACR) Convergence Meeting in Philadelphia.
November 11, 2022
·
3 min read
Genetown
Tremeau Expands Pipeline with Novel Non-Opioid Compound for the Treatment of Acute Pain
Tremeau Pharmaceuticals today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/240,446. Once issued, the patent will provide composition of matter patent protection for Tremeau’s novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.
October 25, 2021
·
6 min read
Genetown
Tremeau Pharmaceuticals ASH 2021 Presentations Highlight Unmet Need for Non-Opioid Pain Treatments for Patients with Bleeding Disorders
Tremeau Pharmaceuticals will present three abstracts highlighting the need for new non-opioid treatment options for bleeding disorder patients during the 63rd American Society of Hematology Annual Meeting and Exposition in Atlanta.
December 13, 2021
·
4 min read
Drug Development
Tremeau Receives May Proceed Notification From FDA For Phase III Program in Acute Migraine For TRM-201 (Rofecoxib)
Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.
June 14, 2022
·
7 min read
Genetown
Tremeau Pharmaceuticals Will Advance Non-Opioid Pain Program with Investment from Gurnet Point Capital
Investment will enable Tremeau to advance the clinical development of TRM-201 (rofecoxib) Tremeau has gained agreement with FDA to initiate a pivotal Phase III trial for TRM-201 in hemophilic arthropathy (HA), a painful and debilitating joint disease If approved, TRM-201 would potentially be the first new oral non-opioid pain treatment in over 15 years, and the first specifically indicated for HA
December 9, 2020
·
6 min read
Press Releases
Kiniksa Pharmaceuticals Provides Corporate Update
January 12, 2026
·
11 min read
Press Releases
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 6, 2026
·
1 min read
Press Releases
Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada
January 13, 2026
·
5 min read
Sponsored
Best Pharmaceutical Label Manufacturers: Reviews and Comparisons
Selecting the ideal pharmaceutical label manufacturer requires careful consideration. This article compares leading companies, highlighting their strengths in regulatory compliance, material performance, serialization, innovation, and sustainability, to help you make an informed decision for your product’s safety and success.
October 27, 2025
·
6 min read
1 of 27,381
Next